Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 125CNS 13Gynecologic 11Sarcoma 8Gastrointestinal 8Tumor-Agnostic 7Thoracic 7Dermatologic 6Lymphoid 5Head & Neck 5Other solid neoplasm 4Endocrine 3Other hematologic neoplasm 2Genitourinary 2NET 1Classical hematology 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ribociclib × Genitourinary × Clear all
NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Thomas Jefferson University

Phase 1/2 Terminated
52 enrolled 31 charts
Genitourinary

Prostatic Neoplasms

NCT02494921 2022-08-31

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

University of California, San Francisco

Phase 1/2 Completed
43 enrolled 22 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡